Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery

 Presented at the ASCRS Symposium on Cataract, IOL and Refractive Surgery, Washington, D.C., USA, April 2005.Funded by Alcon Research, Ltd., Fort Worth, Texas, USA.No author has a financial or proprietary interest in any method or material mentioned.Louis M. Alpern, MD, Robert J. Arleo, MD, Stephen F. Brint, MD, Mike Caplan, MD, Lisa Marie Cibik, MD, Robert J. Cionni, MD, Peter S. Dawson, MD, Arthur M. Fishman, MD, Gary Foster, MD, Henry M. Haley Jr, MD, Jeffrey D. Horn, MD, Ronald A. Landry, MD, Matthew D. Paul, MD, E. Ronald Salvitti, MD, Stephen V. Scoper, MD, Steven Silverstein, MD, and Jeffrey C. Whitsett, MD, served as fellow investigators.

PII: S0886-3350(06)01213-2

doi: 10.1016/j.jcrs.2006.08.043

© 2007 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.